AbCellera Biologics logo
AbCellera Biologics ABCL
$ 9.63 -7.85%
report update icon

Quarterly report 2026-Q3
added 11-09-2026

AbCellera Biologics EPS Ratio | ABCL

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio AbCellera Biologics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-0.49 -0.55 -0.51 0.56 0.56 0.53 -0.01 - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
0.56 -0.55 0.0129

Quarterly EPS Ratio AbCellera Biologics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-0.13 -0.18 -0.14 - -0.19 -0.12 -0.15 - -0.17 -0.13 -0.14 - -0.1 -0.11 -0.14 - 0.09 -0.02 0.59 - -0.08 -0.01 0.43 - -0.02 0.03 -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
0.59 -0.19 -0.0333

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
Kodiak Sciences Kodiak Sciences
KOD
-4.32 $ 97.05 -0.87 % $ 5.16 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
-17.9 $ 0.02 -56.5 % $ 219 usaUSA
BioAtla BioAtla
BCAB
0.27 $ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
1.75 - - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
-3.19 $ 28.91 -8.89 % $ 1.39 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
0.06 $ 13.01 0.74 % $ 1.16 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
-1.15 K - - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-3.27 - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-1.91 - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
13.8 - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.57 - 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-1.96 - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-2.85 - 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
0.18 - - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
-24.7 - - $ 269 M usaUSA
AVROBIO AVROBIO
AVRO
-4.05 - 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
6.6 - - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-1.11 - -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
-3.17 $ 0.23 -12.11 % $ 16.8 K usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
-4.12 - - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-2.46 - -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
0.22 - -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-1.91 - -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
-0.08 - -5.98 % $ 34.1 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
-2.98 - 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
-0.86 - -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
-1.06 - - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
-0.11 - - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
-0.11 - 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
-9.4 - 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
45.4 - - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
2.42 - 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
-0.09 - - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
-12.5 - - $ 528 M usaUSA
Galecto Galecto
GLTO
3.98 - - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
-0.59 - 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
-1.97 - -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
0.64 - -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
0.75 - 1.35 % $ 17.8 M chinaChina
Novavax Novavax
NVAX
2.72 $ 7.47 -3.24 % $ 1.21 B usaUSA
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
-0.88 - -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
-0.9 - - $ 18.8 M usaUSA
IMARA IMARA
IMRA
-1.83 - 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
-2.03 - - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
1.4 - -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
-7.66 - - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
-1.59 - - $ 63.4 M usaUSA